X

Xin Huang

Lineage Cell Therapeutics (United States)

ORCID: 0000-0003-3285-365X

145 papers and 16.3k citations.

PubIndex Score99Top 1% · mid-careerHow it's scored

145Publications

16.3kTotal Citations

First senior author: 2018

Top publicationsby citations

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Massimo Cristofanilli, Sibylle Loibl et al.|New England Journal of Medicine|2018

Cited by 1.3k

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Vivek Subbiah, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2020

Cited by 835

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020

Cited by 766

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with <i>KIT</i> and <i>PDGFRA</i> mutation status

Michael C. Heinrich, G. D. Demetri, Christopher L. Corless et al.|Journal of Clinical Oncology|2006

Cited by 83

Correlation of KIT and PDGFRA mutation status with sunitinib activity in imatinib-resistant GIST

Michael C. Heinrich, George D. Demetri, Robert G. Maki et al.|Unknown|2006

Cited by 0

Indexing the rest of 145 publications…